Adicet Bio Presents Biomarker Data for Off-the-Shelf CAR T Therapy at ACR Convergence 2024

Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial will be presented in…

Read MoreAdicet Bio Presents Biomarker Data for Off-the-Shelf CAR T Therapy at ACR Convergence 2024

Alnylam Reports Interim Phase 1 Data on Nucresiran Showing Rapid, Sustained TTR Knockdown After One Dose

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leader in RNA interference (RNAi) therapeutics, today announced positive new results from its ongoing Phase 1 clinical trial of nucresiran (formerly ALN-TTRsc04), an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of ATTR…

Read MoreAlnylam Reports Interim Phase 1 Data on Nucresiran Showing Rapid, Sustained TTR Knockdown After One Dose

Meridian Health Plan of Illinois Launches Telehealth for YouthCare Members via Blueberry Pediatrics

Meridian Health Plan of Illinois, a provider of managed care services for children, families, and individuals with complex medical needs, has expanded its telehealth program with Blueberry Pediatrics. Initially launched as a pilot in March 2024, the program will now…

Read MoreMeridian Health Plan of Illinois Launches Telehealth for YouthCare Members via Blueberry Pediatrics

Elation Health Survey: 66% of Primary Care Docs Say AI Reduces Administrative Burden

Elation Health, a clinical-first technology company driving innovation in primary care, today shared the results of its latest survey of 100 primary care physicians (PCPs). The survey provides valuable insights into the adoption and impact of artificial intelligence (AI) in…

Read MoreElation Health Survey: 66% of Primary Care Docs Say AI Reduces Administrative Burden